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BACKGROUND: The aim of this study is to find a novel molecular target based on chromosomal alteration and array-based gene
expression analyses in bladder cancer (BC). We investigated a cancer testis antigen, LY6K, which is located on chromosome 8q24.3.
METHODS: Five BC cell lines were subjected to high-resolution array-comparative genomic hybridisation with 244000 probes. The
expression levels of LY6K mRNA were evaluated in BC cell lines and clinical BC specimens by real-time reverse transcription–PCR.
The cell lines were subjected to fluorescence in situ hybridisation of LY6K. Cell viability was evaluated by cell growth, wound healing,
and matrigel invasion assays.
RESULTS: Typical gained loci (Po0.0001) at 6p21.33-p21.32, 8q24.3, 9q34.13, 11q13.1-q14.1, 12q13.12-q13.13, 16p13.3, and
20q11.21-q13.33 were observed in all of the cell lines. We focused on 8q24.3 locus where LY6K gene harbours, and it was the top
upregulated one in the gene profile from the BC cell line. LY6K mRNA expression was significantly higher in 91 BCs than in 37 normal
bladder epitheliums (Po0.0001). Fluorescence in situ hybridisation validated that the high LY6K mRNA expression was due to gene
amplification in the region where the gene harbours. Cell viability assays demonstrated that significant inhibitions of cell growth,
migration, and invasion occured in LY6K knock down BC cell lines; converse phenomena were observed in a stable LY6K transfectant;
and LY6K knockdown of the transfectant retrieved the original phenotype from the LY6K transfectant.
CONCLUSION: Upregulation of the oncogenic LY6K gene located on the gained locus at 8q24.3 may contribute BC development.
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Bladder cancer (BC) is among the five most common malignancies
worldwide, and it is the second most common tumour of the
genitourinary tract and the second most common cause of death in
patients with genitourinary tract malignancies (Jemal et al,2 0 0 9 ) .I n
Japan, the age-standardised mortality rate of BC patients has
increased slightly since 1993 (Qiu et al, 2009). The 5-year survival
rate of patients with non-muscle-invasive BC is close to 90%, whereas
that with muscle-invasive BC is B60%. In spite of various therapeutic
treatments, more than 90% of patients with metastasis die within the
first 5 years (Luke et al,2 0 0 9 ) .T h e r e f o r e ,n e wd i a g n o s t i cm e t h o d s
and new treatments for BC are urgently needed.
Comparative genomic hybridisation (CGH) has facilitated chro-
mosomal characterisation of solid tumours, as it can provide detailed
i n f o r m a t i o no ng a i na n dl o s so ft u m o u rD N Aa c r o s st h ee n t i r e
genome (Inazawa et al, 2004; Ishkanian et al, 2004). Conventional
CGH is widely used to analyse many types of tumours, including BC
(Hovey et al, 1998; Zhao et al,1 9 9 9 ;S i m o net al,2 0 0 0 ;v o nK n o b l o c h
et al, 2000; Mahdy et al, 2001). Recently, microarray-based CGH has
been used by several groups to study copy number instability and
aberration type in BC specimens (Stoehr et al, 2004; Blaveri et al,
2005; Shinoda et al,2 0 0 7 ;Y a m a m o t oet al, 2007; Hurst et al, 2008).
According to the previous BC studies, frequent copy number gains
have been observed at 1q, 3p, 3q, 5p, 6p, 8q, 10p, 11q, 12q, 17q, 19q,
and 20q, whereas copy number losses have been observed at 2q, 4q,
5q, 8p, 9p, 9q, 10q, 11p, 11q, 13q, and 18q. These studies also
demonstrated that the aberration patterns characterise invasive or
non-invasive BC (Hovey et al, 1998; Zhao et al, 1999; Simon et al,
2000; Mahdy et al, 2001; Shinoda et al, 2007; Blaveri et al,2 0 0 9 ) ,a n d
that they could be progression markers for BC (von Knobloch et al,
2000; Stoehr et al,2 0 0 4 ;Y a m a m o t oet al, 2007). Their findings suggest
that promising candidates for tumour-related genes might be located
where the aberrations occur. However, identification of tumour-
related genes is difficult because many genes are involved in the larger
chromosomal areas.
Gene expression profiling by oligonucleotide microarray analysis is
an excellent tool for screening candidate genes that have a tumour
suppressive or oncogenic function in BC (Dyrskjot et al, 2003;
Kawakami et al, 2006). We previously found by microarray analysis
that SKP2 and CKS1 contribute to progression and prognosis in BC
(Kawakami et al, 2007). However, the hundreds of candidate genes
identified by microarray analysis can make it difficult for investiga-
tors to decide which genes to study. Expression analysis of genes
located in regions of gains or losses has shown that the gene
expression level changes along with the gene copy number (Inazawa
et al, 2004; Ishkanian et al, 2004). For example, comparisons of array-
CGH and transcriptome data have shown that 40–60% of the genes in
highly amplified regions are actually overexpressed (Pollack et al,
2002; Heidenblad et al, 2005). Therefore, genome amplifications and
homozygous deletions could be landmarks in cancer cell genomes for
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sidentifying oncogenes and tumour suppressor genes, respectively.
Our group previously integrated array-CGH data analysis with gene
expression profiling to identify candidate genes with oncogenic
function in squamous cell carcinoma (Sugimoto et al, 2009). We have
now used high-resolution array-CGH, performed using about 244000
probes with a length of 60-mer. This proved to be a powerful profiling
tool because it detected more deletions and smaller regions of gains.
LY6K, which is located at 8q24.3, belongs to the LY6 family.
It shows high homology to the low-molecular-weight glycosyl-
phosphatidyl-inositol-anchored molecule, which is either a cell
surface receptor or a secreted granule involved in the cell signaling
pathway (de Nooij-van Dalen et al, 2003). It is also a cancer/testis
antigen, that is, a protein highly expressed in cancer cells but not
in normal cells, except for testis (Scanlan et al, 2004; Ishikawa et al,
2007; Kono et al, 2009). Several groups have shown elevated
expression of LY6K mRNA in human head and neck squamous
cell carcinomas and in lung, oesophageal, and breast cancers
(de Nooij-van Dalen et al, 2003; Lee et al, 2006; Ishikawa et al,
2007). However, little is known about the functional role of LY6K
in BC development. We evaluated LY6K mRNA expression levels
in clinical BC samples and established a stable LY6K transfectant
for functional analysis of the gene.
MATERIALS AND METHODS
Cell lines and culture
We used five human BC cell lines: BOY was established in our
laboratory from an Asian male patient aged 66 diagnosed with
stage III BC with lung metastasis (Takemoto et al, 1997); T24,
UMUC, and J82 were obtained from the American Type Culture
Collection; and KK47 was established at Kanazawa University
(Imao et al, 1999) and kindly provided. These cell lines were
maintained in a minimum essential medium (Sigma-Aldrich,
St Louis, MO, USA) supplemented with 10% fetal bovine serum
(FBS; Equitech-Bio Inc., Kerrville, TX, USA) in a humidified
atmosphere of 5% CO2 and 95% air at 371C.
Array-CGH analysis of BC cell lines
Chromosomal DNA was isolated from the five cell lines using a
FlexiGene (Qiagen, Hilden, Germany) in accordance with the
manufacturer’s protocol. The purity and molecular weight of the
DNA were estimated using agarose gels. The Human Genome CGH
Microarray 244K (Agilent Technologies, Palo Alto, CA, USA),
which contains over 244000 60-mer oligonucleotide probes,
spanning coding and non-coding genomic sequences with median
spacing of 7.4 and 16.5kb, respectively, was used for copy number
measurement. Human genomic DNA (Novagen, Madison, WI,
USA) was used as a reference. Labelling, hybridisation, and
scanning were performed in accordance with the manufacturer’s
protocol. Common aberrant loci were detected using CGH
Analytics Software (Agilent Technologies) with the ADM2 algo-
rithm (|log2 ratio|40.3, P-value o0.05, overlap o0.5; de Smith
et al, 2007). The array-CGH data from this study have been
submitted to the NCBI Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo) under accession no. GSE19714.
Oligonucleotide microarray analysis of BC cell lines
Total RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) in accordance with the manufacturer’s
protocol. The integrity of the RNA was checked by a RNA 6000
Nano Assay kit and a 2100 Bioanalyzer (Agilent Technologies). The
Whole Human Genome Microarray 44K (no. G4112F, Agilent
Technologies), which contains over 41000 60-mer oligonucleotide
probes (GEO platform ID: GPL4133), was used for expression pro-
filing. Hybridisation and washing were performed in accordance
with the instructions of the manufacturer. Because no normal
bladder epithelium cell line is commercially available, we used
human bladder total RNA (Clontech, Mountain View, CA, USA) as
a reference for microarray analysis. The arrays were scanned using
a Packard GSI Lumonics ScanArray 4000 (Perkin Elmer, Boston,
MA, USA). The data obtained were analysed by means of DNASIS
array software (Hitachi Software Engineering, Yokohama, Japan),
which converted the signal intensity for each spot into text format.
The data from each microarray study were normalised using
glucuronidase-b (GUSB) and expressed in absolute numbers. The
oligonucleotide array data are available for reference (NCBI GEO;
http://www.ncbi.nlm.nih.gov/geo; under accession no. GSE19716).
Clinical samples
In all, 91 tissue samples were obtained from BC patients who had
undergone surgical resection at our institution between 2003 and
2007. Also used were 37 pathologically proven normal bladder
epithelium (NBE) samples derived from organ-confined prostate
cancer patients who underwent prostatectomy. The background
and clinicopathological characteristics of the patients are sum-
marised in Table 1. These 128 samples were used for quantitative
real-time reverse transcription PCR (RT–PCR). They were staged
in accordance with the American Joint Committee on Cancer
Union Internationale Contre le Cancer tumour–node–metastasis
classification and histologically graded (Sobin and Wittekind,
2002). Our study was approved by the Bioethics Committee of
Kagoshima University; written previous informed consent and
approval were given by the patients.
Sample preparation and total RNA extraction
Freshly harvested tissues, immediately frozen in liquid nitrogen
and stored at  801C, were dissolved in TRIzol reagent (Invitrogen)
for total RNA extraction following the protocol of the manufac-
turer. Total RNA from peripheral blood lymphocytes (PBLs) of BC
patients were extracted by RNeasy Mini Kit (no. 74106, Qiagen).
RNA density was measured with an Ultrospec 3100 Pro instrument
(Amersham Biosciences, Piscataway, NJ, USA), and RNA quality
was checked with the 2100 Bioanalyzer (Agilent Technologies).
Complementary DNA (cDNA) preparation and
quantitative real-time RT–PCR
First strand cDNA with 1mg total RNA was synthesised using
oligo-deoxythymidine primers of the RT system (Promega, Tokyo,
Japan). Gene-specific PCR products were assayed continuously
Table 1 Patient characteristics
Bladder cancer
Total number 91
Median age (range) 74 (46–100) years
Stage
pTa 20
pT1 27
pT2 20
pT3 6
pT4 4
Unknown 14
Grade
G1 7
G2 41
G3 31
Unknown 12
Normal bladder epithelium
Total number 37
Median age (range) 68 (32–77) years
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City, CA, USA) in accordance with manufacturer’s protocol. The
initial PCR step was a 10-min hold at 951C. The cycles (n¼40)
consisted of a 15-s denaturation step at 951C, followed by 1min
annealing/extension at 631C. All reactions were performed in
triplicate. For quantitative analysis, GUSB served as an internal
control. The TaqMan probes and primers used for LY6K and
GUSB were assay-on-demand gene expression products (Applied
Biosystems). The gene expression relative to normal bladder RNA
(human bladder total RNA, Clontech) was calculated using the
comparative Ct method.
Fluorescence in situ hybridisation (FISH) analysis
A FISH analysis of LY6K amplification was applied to five BC cell
lines with 5-mM thick paraffin-embedded tissues. For FISH probes,
the LY6K locus-containing bacterial artificial chromosome probes
(clone ID; RP11-119A16, RP11-163E23) and the chromosome 8
centromere probe (KBI-20008G, Kreatech Diagnosis, Amsterdam,
The Netherlands) were labelled using a nick translation kit
(Vysis 32-801300, Abbott Molecular Inc., Des Plaines, IL, USA)
with orange-dUTP (Abbott molecular inc.) and PlatinumBright
495 (Kreatech Diagnosis), respectively. Denaturation, hybridisa-
tion, and post-hybridisation washing were carried out in
accordance with Poseidon protocol (Kreatech Diagnosis). The
specimens were counterstained with 4,6-dianidino-2-phenylindone
(DAPI) and examined using a PM-2000 imaging system (HistoRx,
New Haven, CT, USA) equipped with a triple filter set (Chroma,
Bellows Falls, VT, USA): no. 41007 for orange-dUTP, no. 41017 for
PlatinumBright 495, and no. 31000v2 for DAPI.
Immunoblotting
Total protein lysate was prepared with triple detergent lysis
buffer composed of 50mM tris-HCl (pH 8.0), 150mM NaCl,
0.02% NaN3, 0.1% sodium dodecyl sulphate, 1% NP-40, and 0.5%
sodium deoxycholate in the presence of a protease inhibitor
cocktail (Sigma-Aldrich) and 100mM phenylmethylsulfonyl
fluoride. The protein lysate (50mg per lane) was separated by
NuPAGE electrophoresis on 4–12% bis-tris gel (Invitrogen) and
transferred to a polyvinylidene difluoride membrane. Immuno-
blotting was carried out with diluted (1:500) polyclonal LY6K anti-
body (no. IMG_4183, Imgenex, San Diego, CA, USA). After being
washed, the membrane was incubated with goat anti-rabbit IgG
horseradish peroxidase conjugate (Bio-Rad, Hercules, CA, USA).
Specific complexes were visualised with an Amersham ECL Western
blotting detection system (GE Healthcare, Little Chalfont, UK).
Small interfering RNA (siRNA) transfection
We obtained siRNA oligonucleotide target to LY6K (small
interfering (si)-LY6K) from the ON-TARGETplus SMART pool
(L-013771-01-0005; Dharmacon, IL, USA) and non-target as con-
trol (si-control) from the non-targeting pool (D-001810-10-05;
Dharmacon). The T24/LY6K transfectant, and two BC cell lines
(BOY and KK47) were transfected with 10nM siRNA using Lipo-
fectamine RNAiMAX (Invitrogen) reagent following the manufac-
turer’s protocol to evaluate the knockdown effect of siRNA by
quantitative real-time RT–PCR and western blot analysis.
Construction of LY6K expression vectors and transfection
to T24 cells
The LY6K vector was constructed by inserting full-length
LY6K cDNA into the BamH I and Hind III restriction sites of the
pBApo-CMV Neo vector (Takara Bio, Otsu, Japan). The LY6K and
non-targeting (control) vectors were transfected into T24 cells
by calcium phosphate co-precipitation. We did not subject UMUC,
in which the LY6K expression level was lower than in T24, because
its growth was too slow and it was not suitable for transfection.
The T24/LY6K transfectants were split and grown in selective
medium with 1000mgl
 1 of G418. In all, 15 G418-resistant
colonies were chosen and expanded in medium containing
200mgl
 1 of G418. DNA sequences for all constructs were
confirmed by DNA sequencing (Bio Matrix Research Inc., Tokyo,
Japan). Finally, we selected the one with the highest LY6K mRNA
expression among the clones.
XTT assays
Cells were seeded at a density of 3 10
3 cells per well in 96-well
plates and incubated for 48h. Subsequently, cell viability was
determined by the XTT assay following the manufacturer’s
protocol (Roche Applied Sciences, Indianapolis, IN, USA). The
plates were read using an MPR-A4i microplate reader (Tosho,
Tokyo, Japan). All experiments were repeated in triplicate.
Wound healing assay
Cells (2 10
5) were seeded into six-well plates and cultured in
medium containing 10% of FBS to create a confluent monolayer.
They were carefully wounded using 200-ml pipette tips and any cell
debris was removed with phosphate-buffered saline. Microphoto-
graphs were taken, and quantitative analysis of the percentage of
wound healing was calculated using the distance across the wound
at 0h and the indicated time for each cell lines. All experiments
were repeated in triplicate.
Invasion assay
In vitro invasion assay was done using BD BioCoat Matrigel
Invasion Chambers (BD Biosciences, Bedford, MA, USA) in 24-well
plates. Cancer cells (5 10
4) were added to the upper chamber,
and the lower chamber was filled with conditioned medium. After
being incubated for 24h, cells that migrated through the
membrane to the lower surface were stained with Giemsa solution.
Four randomly selected  200 magnification fields were photo-
graphed, and the number of invading cells was counted. All
experiments were repeated in duplicate.
Statistical analysis
The relationship between two groups of findings and numerical
values obtained by real-time PCR and other assay was analysed
with the Mann–Whitney U-test. The analysis software was Expert
StatView (version 4, SAS Institute Inc., Cary, NC, USA); the box
plot style with logarithmic scale was constructed, and the non-
adjusted statistical level of significance of P-value was o0.05. The
95% confidence interval (CI) was calculated using Microsoft Office
Excel (version 2007, Microsoft Corp., Redmond, WA, USA).
RESULTS
Genomic profiling of BC cell lines by array-CGH
To produce a comprehensive survey of genomic aberrations in BC,
five BC cell lines were analysed using array-CGH for patterns of
chromosomal gains and/or losses. Predominantly gained loci
were observed at the several loci (Figure 1A, and Supplementary
Table SI). Among the gained loci, significant gains (Po0.001) at
6p21.33-p21.32, 8q24.3, 9q34.13, 11q13.1-q14.1, 12q13.12-q13.13,
16p13.3, and 20q11.21-q13.33 were observed in all of the cell lines
(100%; Table 2). On the other hand, lost loci were commonly
found at 4p, 4q, 10p, 19p, and 21q in all cell lines (100%; Figure 1A,
and Supplementary Table SII). We focused on the gain locus
at 8q24.3 that was one of the most frequent event in the cell
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slines (Figure 1B, and Table 2), because it has not been studied
in detail for BC. Figure 1C demonstrated that the log ratio of
141.9–146.2Mb on chromosome 8 (8q24.3) was robustly high in
each cell line.
Genomic copy number and expression profile data at
8q24.3
To identify the genes involved in BC development, we evaluated
the expression levels of 91 genes located at 8q24.3 for the five BC
cell lines using an oligo-microarray. We identified 56 genes that
were upregulated more than two-fold in comparison with the
reference RNA (Table 3 upper). The LY6K gene was the top
upregulated one in the gene profile from the BC cell line with a fold
change of 28.62 (relative to normal bladder; Table 3). Hence, we
focused on LY6K being a promising candidate gene for oncogenic
function in BC development. We found that eight LY6 family genes
were located on the region between 141.9 and 146.2Mb on
chromosome 8 (8q24.3; Figure 1C). The expression levels of LY6E,
GML, and LYPD2 were relatively upregulated with an average fold
of 6.37, 3.67, and 1.34, whereas those of LYNX1, LY6H, and LY6D
were not upregulated in the cell lines (Table 3, bottom).
Evaluation of LY6K mRNA expression and the gene
amplification in BC cell lines, and clinical BC samples
Real-time RT–PCR revealed that the expression levels of LY6K
mRNA were commonly low in human normal tissues except for
testis (Figure 2A). In human BC cell lines, LY6K mRNA expression
was abundant in KK47 (184.9-fold relative to normal bladder),
modest in BOY (43.6-fold), and weak in T24 (7.2-fold; Figure 2A).
In clinical samples, LY6K mRNA expression was significantly
higher in the 91 BC samples than in the 37 NBE samples (BC: mean
19.6±3.6, 95% CI 12.4–26.8; NBE 2.4±0.6, 95% CI 1.0–3.7;
Chromosomes
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Figure 1 (A) Array-CGH profiling of five BC cell lines showing recurrence of chromosomal alterations. Integer value recurrence of copy number
alterations in segmented data (y-axis) was plotted for each probe aligned along the x-axis in chromosome order. Red and green bars denote gain and loss of
chromosome material, respectively. The most recurrent regions of DNA copy number gains were on chromosomes 1q, 8q, 11q, and 20q, whereas recurrent
regions of copy number loss were on chromosomes 4p, 4q, 10p, 19p, and 21q. (B) Magnification of chromosome 8 locus in array-CGH profiling. Red and
green denote 40.5 and o0.5 of log2 ratio value. The predominant aberration occurred at 8q24.3. (C) Smoothed copy number profile from 143.2 to
145.6Mb on chromosome 8 (8q24.3) using CGH Analytics Software (Agilent Technologies). A total of 91 genes were located on this region, and LY6K was
located at 143.8Mb. Among the genes, 56 were upregulated more than two-fold compared with the reference RNA in the BC cell lines (Table 3).
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was the upper limit of 95% CI for NBEs, 62 of 91 BCs (68%) were
determined to be samples with high LY6K mRNA expression. The
expression levels of LY6K mRNA in (PBLs of BC patients (n¼4)
were extremely low compared with those of BCs and NBEs,
indicating that PBL contamination does not increase the level of
LY6K mRNA expression in BC tissues. We found no relationship
between the LY6K mRNA expression and clinicopathological
parameters (tumour stage, and grade). To investigate whether
high LY6K mRNA expression depends on gene amplification at the
gene location, we performed FISH. The gene amplification of LY6K
(red signal) in comparison with that of the control centromere
probe (green signal) was higher in BOY and KK47 and lower in
T24 (Figures 3A–C). These results corresponded with the LY6K
mRNA expression levels in these cell lines (Figure 2A).
Effects of LY6K knockdown on cell growth, migration and
invasion
For loss-of-function studies, we used BOY and KK47, in which the
LY6K mRNA was markedly expressed (Figure 2A). Real-time
RT–PCR and immunoblotting demonstrated that LY6K mRNA
expression was substantially lower after si-LY6K transfection to
BOY and KK47 (Figure 4A). After 48-h si-LY6K transfection to
each cell line, XTT assay revealed significant decreases in cell
growth in si-LY6K transfectants in comparison with si-control
transfectants (BOY, 74.1±0.9% and 100±0.6%, respectively,
P¼0.0039; and KK47, 88.2±1.5% and 100±6.5%, respectively,
P¼0.0163; Figure 4B). We found no cytotoxic effect of the
transfection reagent in the transfectants compared with the wild
types. We subjected BOY to wound healing assay, which can
evaluate both cell migration and cell proliferation activity, and
matrigel invasion assay. We did not use KK47 because it was not
suitable for the experiments because of its focal growth pattern.
Wound healing assays demonstrated that the migration into the
wound area was slower in the si-LY6K-transfected BOY than in the
si-control-transfected BOY (54.9±3.6% and 100%, respectively,
Po0.0001; Figure 4C). Matrigel invasion assay showed that the
number of cells invading through the membrane was significantly
lower in the si-LY6K-transfected BOY than in the si-control-
transfected BOY (21.5±5.5% and 100±14.8%, respectively,
P¼0.0016, Figure 4D).
Effects of LY6K overexpression on cell growth, migration,
and invasion
Because T24 showed a lower expression of LY6K mRNA relative to
other cell lines (Figure 2A), we established a stable T24/LY6K
transfectant for gain of function studies. Real-time RT–PCR
showed a high expression level of LY6K mRNA in the transfectant,
whereas it was weak in the T24/non-targeting vector transfec-
tant (control; Figure 5A). Immunoblotting demonstrated a high
expression of 17-kDa LY6K protein in the transfectant, whereas it
was undetectable in the control (Figure 5A). Three independent
XTT assays consistently demonstrated significant acceleration of
cell growth in the transfectant compared with the control (162.1±
1.1% and 100±1.3%, respectively, P¼0.0039; Figure 5B). Wound
healing assays demonstrated that the transfectant migrated into
the wound area more rapidly than the control (163.4±0% and
100±4.4%, respectively, P¼0.0003; Figure 5C). Matrigel invasion
assay showed that the number of cells invading through the
membrane was significantly higher in the transfectant than in the
control (228.3±23.4% and 100±11.3%, respectively, P¼0.0209;
Figure 5D).
Effects of LY6K knockdown in T24/LY6K transfectant
on cell growth, migration, and invasion
To investigate whether LY6K knockdown retrieves the original
phenotype of T24 from that of the T24/LY6K transfectant, we
transfected the transfectant with si-LY6K and subjected it to cell
Table 2 Highly gained loci in BC cell lines
Location Cell lines with gained loci
Chromosome Arm Start End Size No. of probes P-value No. Name
Chr1 p36.13 16443872 16570594 126723 18 0.0052 4 J82, T24, KK47, BOY
Chr1 p36.11 26486288 26582083 95796 15 0.0055 4 T24, BOY, KK47, J82
Chr5 q35.3 179048014 179182725 134712 18 0.0025 4 BOY, KK47, T24, UMUC
Chr6 p22.1 29854670 29923588 68919 9 0.0075 4 UMUC, BOY, KK47, J82
Chr6 p21.33-p21.32 32450499 32450899 401 1 0.0012 5 KK47, UMUC, T24, BOY, J82
Chr8 q13.1 66942022 67492376 550355 52 0.0024 4 T24, BOY, UMUC, J82
Chr8 q23.3-q24.3 115977013 146294242 30317230 2404 0.0009 4 UMUC, J82, KK47, BOY
Chr8 q24.3 141934794 146151558 4216765 496 0.0019 5 T24, UMUC, J82, BOY, KK47
Chr9 p13.3-p13.2 35863145 36917314 1054170 105 0.0030 4 J82, KK47, UMUC, T24
Chr9 q32 116756726 117059739 303014 45 0.0052 4 BOY, KK47, T24, J82
Chr9 q33.3-q34.3 129659306 140696609 11037304 1379 0.0074 4 BOY, T24, J82, KK47
Chr9 q34.13 134348656 135612832 1264177 145 0.0069 5 UMUC, BOY, T24, J82, KK47
Chr11 p13 33673844 33768828 94985 13 0.0083 4 KK47, J82, UMUC, BOY
Chr11 q13.1 65200770 65338587 137818 18 0.0011 5 UMUC, BOY, J82, T24, KK47
Chr11 q13.2-q13.4 66619419 74488807 7869389 807 0.0012 5 BOY, J82, T24, KK47, UMUC
Chr11 q13.3-q14.1 70270969 78189879 7918911 847 0.0050 5 BOY, J82, T24, UMUC, KK47
Chr12 q13.11-q13.2 46756675 56434303 9677629 1216 0.0013 4 T24, UMUC, BOY, KK47
Chr12 q13.12 50421056 50642687 221632 30 0.0078 5 J82, UMUC, T24, KK47, BOY
Chr12 q13.13 53661113 53814590 153478 25 0.0087 5 J82, UMUC, T24, KK47, BOY
Chr16 p13.3 2880932 2923782 42851 10 0.0051 5 BOY, T24, J82, KK47, UMUC
Chr17 q25.2 74890765 74958581 67817 7 0.0088 4 KK47, J82, T24, BOY
Chr20 q11.21-q13.33 29833409 62908815 33075407 3101 0.0027 5 BOY, UMUC, KK47, T24, J82
ChrX p22.2-p22.12 16205283 20103495 3898213 377 0.0070 4 UMUC, J82, BOY, KK47
ChrX q11.1-q28 62707611 152734906 90027296 6184 0.0061 4 KK47, UMUC, J82, BOY
Abbreviations: BC¼bladder cancer; Chr¼chromosome.
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Fold change (relative to normal bladder)
Gene ID Symbol Gene name BOY J82 KK47 T24 UMUC Average
54742 LY6K Lymphocyte antigen 6 complex, locus K 40.92 34.89 41.53 20.08 5.70 28.62
8629 JRK Jerky homolog (mouse) 27.01 7.69 32.34 4.28 6.09 15.48
9401 RECQL4 RecQ protein-like 4 19.39 12.65 16.89 9.96 10.47 13.87
286077 FAM83H Family with sequence similarity 83, member H 9.91 5.43 48.10 4.50 0.22 13.63
23246 BOP1 Block of proliferation 1 19.73 6.17 16.23 6.16 11.67 11.99
65263 PYCRL Pyrroline-5-carboxylate reductase-like 18.65 8.13 15.94 5.00 9.25 11.39
80728 KIAA1688 KIAA1688 protein 14.73 8.10 18.85 6.34 6.88 10.98
4796 NFKBIL2 Nuclear factor of k light polypeptide gene enhancer in B-cells inhibitor-like 2 16.07 5.28 13.46 6.83 10.47 10.42
286075 ZNF707 Zinc-finger protein 707 15.16 5.27 15.58 3.47 5.93 9.08
9684 LRRC14 Leucine-rich repeat containing 14 10.97 9.17 17.30 5.04 2.33 8.96
54512 EXOSC4 Exosome component 4 13.90 4.13 13.84 4.12 6.12 8.42
113655 MFSD3 Major facilitator superfamily domain containing 3 9.41 6.63 11.33 3.33 6.46 7.43
51236 C8orf30A Chromosome 8 open reading frame 30A 10.67 4.59 9.19 3.88 5.83 6.83
4061 LY6E Lymphocyte antigen 6 complex, locus E 6.02 7.31 10.70 2.07 5.74 6.37
9831 ZNF623 Zinc-finger protein 623 8.57 4.81 8.27 1.79 5.91 5.87
7264 TSTA3 Tissue-specific transplantation antigen P35B 7.25 2.93 10.85 3.47 3.72 5.64
1537 CYC1 Cytochrome c-1 7.88 3.96 9.05 1.96 4.55 5.48
23144 ZC3H3 Zinc-finger CCCH-type containing 3 7.22 2.74 9.19 2.41 4.84 5.28
28991 COMMD5 COMM domain containing 5 9.54 4.50 6.22 2.49 3.28 5.20
84875 PARP10 Poly (ADP-ribose) polymerase family, member 10 6.00 6.36 7.75 3.23 2.34 5.14
22827 PUF60 Poly-U-binding splicing factor 60KDa 9.97 2.56 7.85 1.95 3.04 5.08
54108 CHRAC1 Chromatin accessibility complex 1 7.53 2.90 8.54 2.11 4.13 5.04
27161 EIF2C2 Eukaryotic translation initiation factor 2C, 2 9.83 1.98 6.74 1.97 3.14 4.73
84948 TIGD5 Tigger transposable element derived 5 6.12 4.47 6.86 1.61 4.33 4.68
84988 PPP1R16A Protein phosphatase 1, regulatory (inhibitor) subunit 16A 5.06 2.54 10.52 1.83 3.36 4.66
26233 FBXL6 F-box and leucine-rich repeat protein 6 6.95 2.57 7.40 2.64 3.45 4.60
2738 GLI4 GLI-Kruppel family member GLI4 8.28 2.60 5.15 1.90 4.65 4.52
55630 SLC39A4 Solute carrier family 39 (zinc transporter), member 4 10.17 3.38 2.08 3.07 0.84 3.91
6132 RPL8 Ribosomal protein L8 7.12 1.86 7.13 1.33 2.05 3.90
575 BAI1 Brain-specific angiogenesis inhibitor 1 2.50 1.52 2.20 2.53 9.78 3.71
23513 SCRIB Scribbled homologue (Drosophila) 7.46 1.81 5.32 1.56 2.35 3.70
2765 GML Glycosylphosphatidylinositol anchored molecule like protein 5.18 4.34 4.46 2.68 1.68 3.67
5747 PTK2 Protein tyrosine kinase 2 7.73 2.24 2.84 1.76 3.77 3.67
79581 GPR172A G protein-coupled receptor 172A 5.08 2.83 5.33 2.04 2.93 3.64
2875 GPT Glutamic-pyruvate transaminase (alanine aminotransferase) 3.20 3.36 2.28 3.01 6.15 3.60
7553 ZNF7 Zinc-finger protein 7 5.71 2.46 5.24 1.67 2.69 3.55
286122 C8orf31 Chromosome 8 open reading frame 31 4.01 1.86 7.06 1.62 2.38 3.39
286128 ZFP41 Zinc-finger protein 41 homolog (mouse) 6.34 3.50 3.41 2.11 1.50 3.37
81858 SHARPIN SHANK-associated RH domain interactor 5.16 2.77 4.26 1.64 2.61 3.29
114822 RHPN1 Rhophilin, Rho GTPase-binding protein 1 5.25 1.09 5.86 2.45 1.64 3.26
1E+08 UNQ601 LPPA601 3.28 1.92 5.75 1.51 3.23 3.14
79943 ZNF696 Zinc-finger protein 696 5.60 1.52 3.45 2.17 2.91 3.13
8928 FOXH1 Forkhead box H1 4.56 2.32 3.38 2.13 3.24 3.13
8733 GPAA1 Glycosylphosphatidylinositol anchor attachment protein 1 homolog (yeast) 4.50 2.32 4.44 1.22 2.55 3.01
340390 KIAA1875 KIAA1875 3.59 1.93 5.25 1.80 2.23 2.96
340371 NRBP2 Nuclear receptor-binding protein 2 4.13 2.32 4.67 1.18 2.31 2.92
116447 TOP1MT Topoisomerase (DNA) I, mitochondrial 5.50 1.15 4.17 0.97 2.56 2.87
90990 KIFC2 Kinesin family member C2 1.15 4.41 2.32 2.14 4.04 2.81
2907 GRINA Glutamate receptor, ionotropic, N-methyl D-aspartate-associated
protein 1 (glutamate binding)
4.50 2.51 3.57 0.73 1.52 2.57
1936 EEF1D Eukaryotic translation elongation factor 1 delta
(guanine nucleotide exchange protein)
3.20 1.60 4.90 1.16 1.39 2.45
8694 DGAT1 Diacylglycerol O-acyltransferase homolog 1 (mouse) 3.78 1.16 3.97 0.71 2.37 2.40
7564 ZNF16 Zinc-finger protein 16 4.34 1.23 3.58 0.86 1.97 2.40
1584 CYP11B1 Cytochrome P450, family 11, subfamily B, polypeptide 1 3.01 1.91 3.00 1.48 1.92 2.27
100130274 LOC100130274 Similar to hCG1646697 3.40 1.57 2.62 1.52 1.66 2.15
58500 ZNF250 Zinc-finger protein 250 3.47 1.74 2.22 1.02 1.91 2.07
203054 ADCK5 aarF domain containing kinase 5 2.47 2.05 3.23 1.06 1.26 2.01
Other LY6 family genes
137797 LYPD2 LY6/PLAUR domain containing 2 1.75 1.56 1.90 0.91 0.57 1.34
66004 LYNX1 Ly6/neurotoxin 1 1.15 0.60 1.05 0.55 1.10 0.89
57152 SLURP1 Secreted LY6/PLAUR domain containing 1 0.80 0.51 0.72 0.16 0.44 0.53
4062 LY6H Lymphocyte antigen 6 complex, locus H 0.44 0.38 0.41 0.35 0.25 0.37
8581 LY6D Lymphocyte antigen 6 complex, locus D 0.15 0.09 0.18 0.07 0.10 0.12
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sviability studies. Real-time RT–PCR and immunoblotting demon-
strated that LY6K expression was substantially lower after the
si-LY6K transfection (Figure 6A). After 48-h si-LY6K transfection
of the transfectant, XTT assay revealed a significant decrease in cell
growth in the si-LY6K transfectant compared with the si-control
transfectant (84.7±2.0% and 100±1.7%, respectively, P¼0.0039;
Figure 6B). Wound healing assays demonstrated that the
migration into the wound area was slower in the si-LY6K
transfectant than in the si-control transfectant (70.2±3.8% and
100%, respectively, P¼0.0044; Figure 6C). Matrigel invasion assay
showed that the number of cells invading through the membrane
was significantly lower in the si-LY6K transfectant than in the
si-control transfectant (48.2±7.1% and 100±3.6%, respectively,
P¼0.0011; Figure 6D).
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Figure 2 (A) LY6K mRNA expression levels in a panel of normal tissues and BC cell lines from real-time RT–PCR. Gene expressions relative to normal
bladder were calculated using comparative Ct method. The expression levels were commonly low in human normal tissues except for testis; they were high
in two BC cell lines (BOY and KK47). (B) LY6K mRNA expression was significantly higher in clinical BC samples than in normal bladder epithelium (NBE)
samples. Expression levels of LY6K mRNA in peripheral blood lymphocytes (PBL) of BC patients (n¼4) were extremely low. The gene expressions were
determined relative to average for NBE samples.
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Figure 3 Examples of amplification of LY6K gene in BC. Copy number status of gene was determined by fluorescence in situ hybridisation (FISH) in (A)
T24, (B) BOY, and (C) KK47 BC cell lines. Red signals were from LY6K gene probe, and green ones were from centrometric probe (magnification 200).
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In previous studies, chromosomal alteration analysis by CGH and
gene expression profiling by microarray analysis have been
investigated in various cancers (Inazawa et al, 2004; Ishkanian
et al, 2004). Several oncogenes on the gained loci were identified in
BC in the previous array-CGH studies; for example, CCND1,a
member of cyclinD1, FGF3/4, fibroblast growth factors and EMS1,
a regulator of cell adhesion are located on 11q13 (Zaharieva et al,
2003); E2F3, a transcription factor positively regulating cell cycle,
is located on 6p22 (Hurst et al, 2008); and KLK5, a serine protease
involved in cancer progression, is located on 19q13.3 (Shinoda
et al, 2007). However, the large number of candidate genes
identified by array-CGH analysis can make it difficult for
researchers to identify the crucial onco-related ones. Although
differential gene expression demonstrated by microarray-defined
probes can be related to numerical or structural chromosomal
alterations, it is unclear if such changes are also clustered in
distinct chromosomes or genomic regions and whether chromo-
somal alterations always reflect gene expression changes. To
address this issue, we used a high-resolution array containing
about 244000 probes, which enabled exhaustive detection of
chromosomal gain or loss with a median spacing of 7.4kb
of cording regions. We found chromosomal copy number gains on
chromosome arms 6p, 8q, 9q, 11q, 12q, 16p, and 20q and losses on
chromosome arms 4p, 4q, 10p, 19p, and 21q in the five BC cell
lines. Many regions showing copy number alteration matched
those identified in the previous BC studies. We combined array-
CGH data with mRNA expression data from oligo-microarray data
analysis using five BC cell lines and 14 clinical BC samples
(Kawakami et al, 2006). By using three different genome-wide
screenings in BC, we readily identified a new target gene, LY6K,
located at 8q24.3, which has not been identified in array-CGH
research of BC. We found marked copy number gains in most of
the chromosome 8q24.3 region. Several oncogenes including MYC,
PVT1, DDEF1, PTK2, GML, and BOP1 are located on this region,
where the LY6K gene is closely located (Mahdy et al, 2001;
Sarama ¨ki et al, 2006). Our profile showed that these oncogenes
were upregulated more than two-fold in the BC cell lines (Table 3).
These results suggest that the copy number gain of chromosome
8q24.3 has an important role in cancer development through
overexpression of the oncogenes encoded in the region. Thus, gene
profiling based on our multiple genome-wide screening enable the
use of strategies for finding novel oncogenes in human BC.
Several investigations found overexpression of LY6K in several
human malignancies, such as head and neck squamous cell
carcinomas and breast, lung, and oesophageal cancers (de Nooij-
van Dalen et al, 2003; Scanlan et al, 2004; Lee et al, 2006; Ishikawa
et al, 2007; Choi et al, 2009; Kono et al, 2009). LY6K over-
expression is associated with poorer prognosis for patients with
non-small cell lung carcinomas as well as oesophageal squamous
cell carcinomas (Ishikawa et al, 2007). The migration activity was
significantly higher in LY6K-transfected breast cancer cell lines
(Choi et al, 2009). We established a permanent LY6K-transfected
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Figure 4 Effects of LY6K knockdown on cell growth. (A) LY6K mRNA expressions were markedly repressed in si-LY6K transfectants (BOY and KK47) in
comparison with si-control transfectants. (B) Cell viability as determined by XTT assay. Greater growth inhibition was observed in the si-LY6K transfectants
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including cell growth and invasion activity as well as its migration
activity, all of which were retrieved by si-LY6K transfection. These
findings suggest that LY6K functions as an oncogenic molecule
and contributes to the development of various cancers. LY6K
is also a cancer/testis antigen. A new immunotherapy using
established cytotoxic T lymphocyte targeting LY6K was studied in
lung and oesophageal cancer cell lines (Ishikawa et al, 2007; Kono
et al, 2009), meaning that LY6K is a promising target for BC
immunotherapy. The other members of the LY6 family genes are
mostly located at 8q24.3 (LY6D, LY6E, LY6H, SLURP1, LYPD2,
LYNX1, and GML). The functional roles of these genes are not
completely understood. Previous studies demonstrated that LY6D
is highly expressed in colorectal cancer (Reichling et al, 2005)
and that also LY6E is in pancreatic cancer stem cells (Gou et al,
2007). LY6E and GML as well as LY6K were consistently among the
top 40 upregulated genes in our profile. Thus, the LY6 family
genes may have an oncogenic function in cooperation. However,
our profile also showed that some of the LY6 family genes were
not upregulated even though they are located on 8q24.3, wherein
predominantly gained loci were located in the CGH array study.
These results indicate that another epigenetic pathway might
repress the mRNA expression of these genes. Further
studies are necessary to elucidate whether LY6K expression in
clinical specimen is actually regulated by the gained locus of
8q24.3.
The LY6 family members are assumed to have functions related to
cell signalling and/or cell adhesion (de Nooij-van Dalen et al, 2003;
Lee et al, 2006; Choi et al, 2009) although the precise role of LY6K in
carcinogenesis is still unknown. To gain further insight into which
genes are affected by LY6K gene expression, we performed gene
expression analysis of the LY6K transfectant. The functional
annotations of the upregulated genes after LY6K transfection were
distributed among nine categories including cell cycle, transcription,
and signal transduction. Several clusters of genes in our profile are
oncogenic molecules contributing to cancer development, for
example, E2F genes (Hurst et al, 2008), insulin-like growth factors
(Huszar et al, 2009), cell division cycle genes (Chen et al, 2006), a-/b-
tubulines (Canta et al, 2009), and zinc finger proteins (Gommans
et al, 2005; Supplementary Table SIII). These results suggest that
LY6K promotes and activates cell-cycle-related genes in BC. Further
investigation is necessary to test this hypothesis. In our cohort, there
was no significant relationship between the LY6K mRNA expression
and clinicopathological parameters. Regional epigenetic silencing and
activation of multiple genes unrelated to chromosomal alterations
may affect the pathological parameters of individual tumours. More
precise studies with various experiments are needed to explain these
phenomena.
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have an oncogenic activity in human BC and chromosomal gain locus
of 8q24.3 where LY6K gene harbours may have a critical role for BC
development. We conducted experiments to clarify the gain and loss
of functions using a stable LY6K-transfected BC cell line and found
t h a tL Y 6 Km i g h th a v ea no n c o g e n i cf u n c t i o n ,s u g g e s t i n gt h a ti ti sa
promising candidate for molecular targeting of human BC.
ACKNOWLEDGEMENTS
We thank Ms M Miyazaki for her excellent laboratory assistance.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T,
Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM (2005) Bladder
cancer stage and outcome by array-based comparative genomic
hybridization. Clin Cancer Res 11: 7012–7022
Canta A, Chiorazzi A, Cavaletti G (2009) Tublin: a target for antineoplastic
drugs into the cancer cells but also in the peripheral nervous system.
Curr Med Chem 16: 1315–1324
Chen JS, Lin SY, Tso WL, Yeh GC, Lee WS, Tseng H, Chen LC, Ho YS
(2006) Checkpoint kinase 1-mediated phosphorylation of Cdc25C
and bad proteins are involved in antitumor effects of loratadine-induced
G2/M phase cell-cycle arrest and apoptosis. Mol Carcinog 45:
461–478
Choi SH, Kong HK, Park SY, Park JH (2009) Metastatic effect of LY-6K gene
in breast cancer cells. Int J Oncol 35: 601–607
de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ,
Stigter-van Walsum M, SnoHw GB, Brakenhoff RH (2003) Characteriza-
tion of the human Ly-6 antigens, the newly annotated member Ly-6K
included, as molecular markers for head-and-neck squamous cell
carcinoma. Int J Cancer 103: 768–774
de Smith AJ, Tsalenko A, Sampas N, Scheffer A, Yamada NA, Tsang P, Ben-
Dor A, Yakhini Z, Ellis RJ, Bruhn L, Laderman S, Froguel P, Blakemore
AL (2007) Array CGH analysis of copy number variation identifies 1284
new genes variant in healthy white males: implications for association
studies of complex diseases. Hum Mol Genet 16: 2783–2794
0 h
27 h
W
o
u
n
d
 
c
l
o
s
u
r
e
(
%
 
o
f
 
s
i
-
c
o
n
t
r
o
l
)
I
n
v
a
s
i
o
n
 
c
e
l
l
 
n
u
m
b
e
r
(
%
 
o
f
 
s
i
-
c
o
n
t
r
o
l
) 100
80
40
0
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
s
i
-
c
o
n
t
r
o
l
)
100
80
60
0
P = 0.0044
P = 0.0011
P = 0.0039
50
100
0
L
Y
6
K
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
(
%
 
o
f
 
s
i
-
c
o
n
t
r
o
l
)
100
50
0
LY6K
GAPDH
si-control
si-control
si-control
T24/LY6K-TF
T24/LY6K-TF T24/LY6K-TF
T24/LY6K-TF
si-LY6K
si-control si-LY6K si-control si-LY6K
si-LY6K
si-LY6K
si-control si-LY6K
Figure 6 Effects of LY6K knockdown in T24/LY6K transfectant on cell growth, migration, and invasion. (A) LY6K mRNA expressions were markedly lower
after si-LY6K-transfection of T24/LY6K transfectant (TF) than in the si-control transfectant. (B) Cell viability as determined by XTT assay. Significant growth
inhibition was observed in the si-LY6K transfectant. (C) Cell migration activity by the wound healing assay. A significant inhibition of cell migration was
observed in the si-LY6K transfectant. (D) Cell invasion activity by the matrigel invasion assay. The number of cells invading through the membrane was
significantly decreased in the si-LY6K transfectant.
LY6K is novel molecular target in bladder cancer
R Matsuda et al
385
British Journal of Cancer (2011) 104(2), 376–386 & 2011 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sDyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-
Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of
bladder carcinoma using microarrays. Nat Genet 33: 90–96
Gommans WM, Haisma HJ, Rots MG (2005) Engineering zinc finger
protein transcription factors: the therapeutic relevance of switching
endogenous gene expression on or off at command. J Mol Biol 354:
507–519
Gou S, Liu T, Wang C, Yin T, Li K, Yang M, Zhou J (2007) Establishment of
clonal colony-forming assay for propagation of pancreatic cancer cells
with stem cell properties. Pancreas 34: 429–435
Heidenblad M, Lindgren D, Veltman JA, Jonson T, Mahlama ¨ki EH,
Gorunova L, van Kessel AG, Schoenmakers EF, Ho ¨glund M (2005)
Microarray analyses reveal strong influence of DNA copy number
alterations on the transcriptional patterns in pancreatic cancer:
implications for the interpretation of genomic amplifications. Oncogene
24: 1794–1801
Hovey RM, Chu L, Balazs M, DeVries S, Moore D, Sauter G, Carroll PR,
Waldman FM (1998) Genetic alterations in primary bladder cancers and
their metastases. Cancer Res 58: 3555–3560
Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA (2008)
Inactivation of the Rb pathway and overexpression of both isoforms of
E2F3 are obligate events in bladder tumours with 6p22 amplification.
Oncogene 27: 2716–2727
Huszar D, Theoclitou ME, Skolnik J, Herbst R (2009) Kinesin motor
proteins as targets for cancer therapy. Cancer Metastasis Rev 28:
197–208
Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M (1999)
Dominant role of E-cadherin in the progression of bladder cancer. J Urol
161: 692–698
Inazawa J, Inoue J, Imoto I (2004) Comparative genomic hybridization
(CGH)-arrays pave the way for identification of novel cancer-related
genes. Cancer Sci 95: 559–563
Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y,
Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N,
Nakamura Y, Daigo Y (2007) Cancer-testis antigen lymphocyte antigen
6 complex locus K is a serologic biomarker and a therapeutic target for
lung and esophageal carcinomas. Cancer Res 67: 11601–11611
Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP,
Snijders A, Albertson DG, Pinkel D, Marra MA, Ling V, MacAulay C,
Lam WL (2004) A tiling resolution DNA microarray with complete
coverage of the human genome. Nat Genet 36: 299–303
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics,
2009. CA Cancer J Clin 59: 225–249
Kawakami K, Enokida H, Tachiwada T, Gotanda T, Tsuneyoshi K, Kubo H,
Nishiyama K, Takiguchi M, Nakagawa M, Seki N (2006) Identification of
differentially expressed genes in human bladder cancer through genome-
wide gene expression profiling. Oncol Rep 16: 521–531
Kawakami K, Enokida H, Tachiwada T, Nishiyama K, Seki N, Nakagawa M
(2007) Increased SKP2 and CKS1 gene expression contributes to the
progression of human urothelial carcinoma. J Urol 178: 301–307
Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K,
Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H (2009) Vaccination with
multiple peptides derived from novel cancer-testis antigens can induce
specific T-cell responses and clinical responses in advanced esophageal
cancer. Cancer Sci 100: 1502–1509
Lee JW, Lee YS, Yoo KH, Lee KH, Park K, Ahn T, Ko C, Park JH (2006)
LY-6K gene: a novel molecular marker for human breast cancer. Oncol
Rep 16: 1211–1214
Luke C, Tracey E, Stapleton A, Roder D (2009) Exploring contrary trends in
bladder cancer incidence, mortality and survival: implications for
research and cancer control. Intern Med J 40: 357–362
Mahdy E, Pan Y, Wang N, Malmstro ¨m PU, Ekman P, Bergerheim U (2001)
Chromosome 8 numerical aberration and C-MYC copy number gain
in bladder cancer are linked to stage and grade. Anticancer Res 21:
3167–3173
Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani
R, Botstein D, Borresen-Dale AL, Brown PO (2002) Microarray analysis
reveals a major direct role of DNA copy number alteration in the
transcriptional program of human breast tumors. Proc Natl Acad Sci USA
99: 12963–12968
Qiu D, Katanoda K, Marugame T, Sobue T (2009) A joinpoint regression
analysis of long-term trends in cancer mortality in Japan (1958-2004).
Int J Cancer 124: 443–448
Reichling T, Goss KH, Carson DJ, Holdcraft RW, Ley-Ebert C, Witte D,
Aronow BJ, Groden J (2005) Transcriptional profiles of intestinal tumors
in Apc(Min) mice are unique from those of embryonic intestine and
identify novel gene targets dysregulated in human colorectal tumors.
Cancer Res 65: 166–176
Sarama ¨ki OR, Porkka KP, Vessella RL, Visakorpi T (2006) Genetic
aberrations in prostate cancer by microarray analysis. Int J Cancer 119:
1322–1329
Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review,
standardization, and commentary. Cancer Immun 4: 1
Shinoda Y, Kozaki K, Imoto I, Obara W, Tsuda H, Mizutani Y, Shuin T,
Fujioka T, Miki T, Inazawa J (2007) Association of KLK5 overexpression
with invasiveness of urinary bladder carcinoma cells. Cancer Sci 98:
1078–1086
Simon R, Burger H, Semjonow A, Hertle L, Terpe HJ, Bocker W (2000)
Patterns of chromosomal imbalances in muscle invasive bladder cancer.
Int J Oncol 17: 1025–1029
Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours,
6th edn. International Union Against Cancer (UICC). Wiley-Liss: New
York. pp 199–202
Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl
E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstaedter
F, Rosenthal A, Baylin SB, Pilarsky C, Hartmann A (2004) Deletions of
chromosome 8p and loss of sFRP1 expression are progression markers of
papillary bladder cancer. Lab Invest 84: 465–478
Sugimoto T, Seki N, Shimizu S, Kikkawa N, Tsukada J, Shimada H,
Sasaki K, Hanazawa T, Okamoto Y, Hata A (2009) The galanin signaling
cascade is a candidate pathway regulating oncogenesis in human
squamous cell carcinoma. Genes Chromosomes Cancer 48: 132–142
Takemoto M, Shirahama T, Miyauchi T, Matsusako T, Kaneda N,
Muramatsu H, Ozawa M, Ohi Y, Muramatsu T (1997) Metanestin, a
glycoprotein with metastasis-associated expression in transitional cell
carcinoma of the urinary bladder. Int J Cancer 74: 7–14
von Knobloch R, Bugert P, Jauch A, Ka ¨lble T, Kovacs G (2000) Allelic
changes at multiple regions of chromosome 5 are associated with
progression of urinary bladder cancer. J Pathol 190: 163–168
Yamamoto Y, Chochi Y, Matsuyama H, Eguchi S, Kawauchi S, Furuya T,
Oga A, Kang JJ, Naito K, Sasaki K (2007) Gain of 5p15.33 is associated
with progression of bladder cancer. Oncology 72: 132–138
Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G,
Kno ¨nagel H, Rist M, Wilber K, Hering F, Scho ¨nenberger A, Flury R, Ja ¨ger
P, Fehr JL, Mihatsch MJ, Gasser T, Sauter G, Toncheva DI (2003) High-
throughput tissue microarray analysis of 11q13 gene amplification
(CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 201:
603–608
Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T, Ackermann D,
Schmid U, Moch H, Mihatsch MJ, Gasser TC, Sauter G (1999)
Chromosomal imbalances in noninvasive papillary bladder neoplasms
(pTa). Cancer Res 59: 5687–5691
LY6K is novel molecular target in bladder cancer
R Matsuda et al
386
British Journal of Cancer (2011) 104(2), 376–386 & 2011 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s